Class Action Lawsuit Announced for Zoetis Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Zoetis Inc. for securities purchased between January 14, 2025, and May 6, 2026, reflecting significant legal risks that could impact the company's stock performance.
- Investor Rights Protection: Investors joining the lawsuit can seek compensation without upfront costs through a contingency fee arrangement, which reduces financial burdens and encourages more affected parties to participate in the litigation.
- Market Share Decline: The lawsuit claims that Zoetis' veterinarian prescription growth and market share have sharply weakened due to FDA safety warnings, particularly affecting its flagship products Librela and Simparica Trio, indicating severe challenges in a competitive market.
- Law Firm Credibility: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 77.590
Low
130.00
Averages
154.20
High
200.00
Current: 77.590
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Releases 2025 Sustainability Report Highlighting Key Achievements
- Sustainability Goals Achieved: The Zoetis Foundation successfully distributed $35 million in grants from 2021 to 2025, supporting veterinary professionals and livestock farmers while advancing humanitarian aid, showcasing the company's commitment to social responsibility.
- Innovative Vaccine Approvals: The company received conditional licenses for its H5N2 vaccine in the U.S. and Canada to combat avian influenza in poultry and dairy cattle, marking Zoetis's scientific innovation capabilities and market leadership in animal health.
- Significant Emission Reductions: Since 2021, Zoetis has reduced its Scope 1 and 2 emissions by 29%, completing over 100 carbon reduction projects in 2025 alone, which are expected to prevent approximately 5,000 metric tons of CO2e annually, reflecting the company's strong commitment to environmental sustainability.
- Volunteer Service Exceeded Goals: In 2025, employees reported over 20,700 hours of volunteer time, exceeding the company's stated goal by 104%, demonstrating Zoetis's success in promoting employee engagement in social responsibility initiatives.
See More
Class Action Lawsuit Announced for Zoetis Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Zoetis Inc. for securities purchased between January 14, 2025, and May 6, 2026, reflecting significant legal risks that could impact the company's stock performance.
- Investor Rights Protection: Investors joining the lawsuit can seek compensation without upfront costs through a contingency fee arrangement, which reduces financial burdens and encourages more affected parties to participate in the litigation.
- Market Share Decline: The lawsuit claims that Zoetis' veterinarian prescription growth and market share have sharply weakened due to FDA safety warnings, particularly affecting its flagship products Librela and Simparica Trio, indicating severe challenges in a competitive market.
- Law Firm Credibility: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Zoetis Faces Securities Class Action Over Concealed FDA Warnings
- Stock Price Collapse: Zoetis shares plummeted 21.5%, losing nearly $24 per share, as the market learned that the company's Companion Animal franchise was under greater pressure than disclosed, significantly impacting investor confidence and market capitalization.
- FDA Warning Concealment: In December 2024, the FDA issued a warning letter detailing severe neurological side effects in dogs treated with Librela, yet management minimized its significance, leading to a sharp decline in veterinarian confidence in prescribing the drug.
- Intensifying Competitive Threat: The lawsuit alleges that Zoetis concealed the rapid market share capture by Elanco's new therapies, with management previously claiming a
See More
Screwworm Fears Spark Market Activity for Zoetis and Elanco
- Market Reaction: The discovery of New World screwworm in Texas has led to shares of Zoetis and Elanco Animal Health rising nearly 4% and 2% respectively on Thursday, indicating strong market interest in animal health products.
- Surge in Options Trading: Options volume for Zoetis surged to almost 20 times the daily average, with nearly 12,000 contracts traded, including the purchase of 4,200 call options, reflecting investor optimism about the company's future performance.
- FDA Support: Zoetis received conditional FDA approval last year for an injectable product that treats and prevents reinfestation of the screwworm, and last month the FDA issued emergency use authorization, bolstering market confidence in the product.
- Beef Supply Risks: While cattle futures are up over 1%, the potential spread of the screwworm could strain beef supply, leading to market volatility among American consumers who favor fast food, highlighting the economic implications of this event.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
Zoetis Releases 2025 Sustainability Report Highlighting Key Achievements
- Sustainability Goals Achieved: The Zoetis Foundation successfully distributed $35 million in grants from 2021 to 2025, supporting veterinary professionals and livestock farmers while advancing humanitarian aid, showcasing the company's commitment to social responsibility.
- Innovative Vaccine Approvals: The company received conditional licenses for its H5N2 vaccine in the U.S. and Canada to combat avian influenza in poultry and dairy cattle, marking Zoetis's scientific innovation capabilities and market leadership in animal health.
- Significant Emission Reductions: Since 2021, Zoetis has reduced its Scope 1 and 2 emissions by 29%, completing over 100 carbon reduction projects in 2025 alone, which are expected to prevent approximately 5,000 metric tons of CO2e annually, reflecting the company's strong commitment to environmental sustainability.
- Volunteer Service Exceeded Goals: In 2025, employees reported over 20,700 hours of volunteer time, exceeding the company's stated goal by 104%, demonstrating Zoetis's success in promoting employee engagement in social responsibility initiatives.
See More
Class Action Lawsuit Announced for Zoetis Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Zoetis Inc. for securities purchased between January 14, 2025, and May 6, 2026, reflecting significant legal risks that could impact the company's stock performance.
- Investor Rights Protection: Investors joining the lawsuit can seek compensation without upfront costs through a contingency fee arrangement, which reduces financial burdens and encourages more affected parties to participate in the litigation.
- Market Share Decline: The lawsuit claims that Zoetis' veterinarian prescription growth and market share have sharply weakened due to FDA safety warnings, particularly affecting its flagship products Librela and Simparica Trio, indicating severe challenges in a competitive market.
- Law Firm Credibility: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
See More
US Stocks Close Mixed: Dow Hits All-Time High
- Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
- Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
- Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
- Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
See More
Zoetis Faces Securities Class Action Over Concealed FDA Warnings
- Stock Price Collapse: Zoetis shares plummeted 21.5%, losing nearly $24 per share, as the market learned that the company's Companion Animal franchise was under greater pressure than disclosed, significantly impacting investor confidence and market capitalization.
- FDA Warning Concealment: In December 2024, the FDA issued a warning letter detailing severe neurological side effects in dogs treated with Librela, yet management minimized its significance, leading to a sharp decline in veterinarian confidence in prescribing the drug.
- Intensifying Competitive Threat: The lawsuit alleges that Zoetis concealed the rapid market share capture by Elanco's new therapies, with management previously claiming a
See More
Screwworm Fears Spark Market Activity for Zoetis and Elanco
- Market Reaction: The discovery of New World screwworm in Texas has led to shares of Zoetis and Elanco Animal Health rising nearly 4% and 2% respectively on Thursday, indicating strong market interest in animal health products.
- Surge in Options Trading: Options volume for Zoetis surged to almost 20 times the daily average, with nearly 12,000 contracts traded, including the purchase of 4,200 call options, reflecting investor optimism about the company's future performance.
- FDA Support: Zoetis received conditional FDA approval last year for an injectable product that treats and prevents reinfestation of the screwworm, and last month the FDA issued emergency use authorization, bolstering market confidence in the product.
- Beef Supply Risks: While cattle futures are up over 1%, the potential spread of the screwworm could strain beef supply, leading to market volatility among American consumers who favor fast food, highlighting the economic implications of this event.
See More
Dow Jones Hits All-Time High Amid Mixed Market Performance
- Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
- Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
- Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
- Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
See More
